WO2018214943A1 - 一种冻存细胞制剂及细胞复苏方式 - Google Patents

一种冻存细胞制剂及细胞复苏方式 Download PDF

Info

Publication number
WO2018214943A1
WO2018214943A1 PCT/CN2018/088246 CN2018088246W WO2018214943A1 WO 2018214943 A1 WO2018214943 A1 WO 2018214943A1 CN 2018088246 W CN2018088246 W CN 2018088246W WO 2018214943 A1 WO2018214943 A1 WO 2018214943A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
preparation
frozen
cryopreservation
Prior art date
Application number
PCT/CN2018/088246
Other languages
English (en)
French (fr)
Inventor
张丽
王飞
何佳平
林南静
刘丽萍
刘欣
李超
余舒倩
胡永来
赵佳维
孙哲
刘晓雨
Original Assignee
西比曼生物科技（上海）有限公司
西比曼生物科技（无锡）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西比曼生物科技（上海）有限公司, 西比曼生物科技（无锡）有限公司 filed Critical 西比曼生物科技（上海）有限公司
Priority to NZ759568A priority Critical patent/NZ759568A/en
Priority to JP2020515812A priority patent/JP7303184B2/ja
Priority to KR1020197038096A priority patent/KR102350423B1/ko
Priority to EP18805534.7A priority patent/EP3632207A4/en
Priority to AU2018272688A priority patent/AU2018272688B2/en
Priority to US16/616,216 priority patent/US20200170242A1/en
Publication of WO2018214943A1 publication Critical patent/WO2018214943A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Definitions

  • the present invention belongs to the field of cell therapy, and in particular, the present invention provides a no-washable intravenously inoculated frozen cell preparation, and simplifies the use of the frozen cell preparation.
  • Fresh cells are typically used for intravenous or topical infusion, or cryopreserved cells are washed and used.
  • Fresh cells usually have an expiration date of less than 8 hours before clinical use, which is not conducive to long-distance transportation, and can not adapt to changes in clinical patients. Therefore, if it is necessary to apply to cells in the therapeutic field, it is bound to involve the process of cryopreservation and resuscitation of cells.
  • cryopreservation in the laboratory, resuscitation washing of frozen cells is usually performed in a clean environment (such as in a sterile room) and requires the operation of a professional biotech technician.
  • a clean environment such as in a sterile room
  • the process of cryopreservation is carried out in a general hospital, unable to provide a sterile room environment, and lack of personnel with corresponding experimental skills, which limits the promotion of cell therapy.
  • the invention adopts a no-clean cryopreservation solution for preparation of a cell frozen preparation, and the cell resuscitation and dilution can be carried out for clinical use by a simple dispensing operation. Effectively solve the above problems in the field of cell therapy.
  • a cryopreserved (frozen) cell preparation comprising:
  • a cryopreservation solution comprising: an aqueous solution of sodium chloride, a protective protein, and dimethyl sulfoxide.
  • the cell is a cell selected from the group consisting of a primary T cell, a T cell after expansion, a T cell after gene transduction, a stem cell, or a combination thereof.
  • the cells are cells selected from the group consisting of suspension cultured cells and adherent cultured cells.
  • the adherent cultured cells are pre-digested and suspended prior to preparation of the cryopreserved preparation.
  • the cell density ranges from 1 ⁇ 10 5 to 5 ⁇ 10 8 /ml.
  • the sodium chloride concentration in the preparation is from 0.85% to 0.95% (w/v).
  • the protective protein concentration is from 10% to 90% (w/v) in the formulation.
  • the protective protein has a protective protein concentration of 10-30% (w/v).
  • the protective protein concentration of the formulation is 15-25% (w/v).
  • the dimethyl hydrazine concentration is from 5% to 40% (v/v) in the formulation.
  • the concentration of dimethyl hydrazine in the preparation is from 5% to 20% (v/v).
  • the dimethyl hydrazine concentration is 8% to 12% (v/v) in the preparation.
  • the method comprises the steps of:
  • the frozen diluent comprises the following components: An aqueous solution of sodium chloride, and a protective protein;
  • the container is a frozen or frozen tube.
  • the cryopreservation diluent comprises: an aqueous solution of sodium chloride, and a protective protein.
  • the sodium chloride concentration in the cryopreservation diluent is from 0.85% to 0.95% (w/v).
  • the concentration of the protective protein in the cryopreserved diluent is from 10% to 90% (w/v).
  • the protective protein has a protective protein concentration of 10-30% (w/v).
  • the protective protein concentration of the formulation is 15-25% (w/v).
  • a cryopreservation cell resuscitation method comprising the steps of:
  • the resuscitation further comprises the steps of: detecting the viability of the cells, and if the viability meets the requirements for use, for clinical use.
  • the thermostatic device is a thermostatic water bath.
  • the cell thawing time is from 30 seconds to 3 minutes.
  • the injection carrier is an intravenously injectable solution, preferably selected from the group consisting of sodium chloride injection, compound electrolyte injection, and amino acid injection.
  • Figure 1 is a graph showing changes in cell viability before and after cryopreservation in Example 1;
  • Figure 2 is a graph showing the cell proliferation ability after cryopreservation in Example 1;
  • Figure 3 is a graph showing the comparison of tumor antigen response ability of CAR-T cells before and after cryopreservation in Example 1;
  • Figure 4 shows a comparison of different cryopreservation methods (programs).
  • the inventors designed a simple cell cryopreservation-recovery method and the corresponding cryopreservation solution used.
  • the method can be conveniently performed by a medical professional in an ordinary laboratory environment, and thus can be used as a cryopreservation-recovery method in a cell therapy process. Based on the above findings, the inventors completed the present invention.
  • freeze cell preparation and “freeze cell preparation” are used interchangeably and refer to a preparation containing therapeutically active cells that is preserved at low temperatures (eg, at -80 ° C, or in a liquid nitrogen environment).
  • the cryopreserved (frozen) cell preparation of the present invention comprises the following components:
  • a cryopreservation solution comprising: an aqueous solution of sodium chloride, a protective protein, and dimethyl sulfoxide.
  • the cell is an active cell which can be used for cell therapy, and the kind thereof is not particularly limited.
  • the cell is a cell selected from the group consisting of primary T cells, after expansion and culture. T cells, T cells after gene transduction, stem cells, or a combination thereof.
  • the cell type of the present invention is not particularly limited, and in another preferred embodiment, the cell is a cell selected from the group consisting of a suspension cultured cell and an adherent cultured cell.
  • the adherent cultured cells are pre-digested and suspended prior to preparation of the cryopreserved preparation.
  • the cell density range is not particularly limited and may be, for example, 1 ⁇ 10 5 - 5 ⁇ 10 8 /ml.
  • the sodium chloride concentration is from 0.85% to 0.95% (w/v).
  • the protective protein concentration of the formulation is from 10% to 90% (w/v).
  • the dimethyl hydrazine concentration is from 5% to 40% (v/v) in the formulation.
  • the invention also provides a method for cryopreservation-recovery of cells, the method comprising the steps of:
  • the frozen diluent comprises the following components: An aqueous solution of sodium chloride, and a protective protein;
  • the ratio of the above two may be slightly different depending on the type of cells to be frozen.
  • the container is not particularly limited, and is preferably a container which can pierce the surface of the container with a syringe to perform liquid absorption.
  • the container is a frozen or frozen tube.
  • cryopreserved cells can be resuscitated in a conventional non-sterile environment.
  • the resuscitation process comprises the steps of:
  • the resuscitation further comprises the steps of: detecting the viability of the cells, and if the viability meets the requirements for use, for clinical use.
  • the constant temperature device is not particularly limited and may be a thermostatic device commonly used in a laboratory (such as a constant temperature water bath).
  • the cell thawing time is from 30 seconds to 3 minutes.
  • the injection carrier is not particularly limited, and may preferably be an intravenously solution, more preferably selected from the group consisting of sodium chloride injection, compound electrolyte injection, and amino acid injection.
  • the collected cells are washed with physiological saline prior to cryopreservation to ensure that the residues meet the clinical use requirements of the product.
  • the cryopreservation diluent has the same composition as the cryopreservation solution except that it does not contain dimethyl sulfoxide. According to the cryopreservation specification, resuspend the cells with the frozen diluent to make the cell concentration 2 times the final concentration, and then slowly add an equal volume of the cryopreservation solution and mix well. The cell suspension was transferred to a cryopreservation bag (or a cryotube), and the temperature was lowered using a cooling rate of 1-2 ° C / min. When cooling to below 80 °C, transfer to a liquid nitrogen refrigerator for storage.
  • the frozen preparation was taken out from the liquid nitrogen refrigerator at the time of use, and quickly thawed at 37 °C. After thawing, transfer to physiological saline with an injection or a single use connector.
  • the live cell assay was performed on the diluted cell preparation. The live rate meets the requirements for use and is used clinically.
  • the cell preparation prepared by the present invention can maintain a high cell viability after long-term storage, and is convenient for long-distance transportation from a preparation unit to a hospital.
  • the cell cryopreservation preparations according to the present invention all use adjuvant-grade or pharmaceutical-grade reagents, and can be safely applied in clinical practice.
  • the resuscitation operation of the frozen cell preparation by the use mode of the present invention can eliminate the stringent requirements of the cell preparation operation on the aseptic environment, and can enable an untrained nurse to easily grasp the recovery of the frozen cells. Maintain high cell viability.
  • the resuscitation operation of the frozen cell preparation by the use mode of the present invention can maintain the biological activity of the cells.
  • the frozen storage container of the frozen cell preparation is a frozen storage bag.
  • the cell type is CAR-T cells. Freeze the specifications 2 ⁇ 10 7 /10ml.
  • the components of the frozen cell preparation are shown in the table below.
  • the CAR-T cells were frozen for 3 months with 100 ml, and then thawed in a 37 ° C water bath for 2 minutes, and the thawed cells were diluted with a syringe into 100 ml of physiological saline. The diluted cells were taken for viability assay, tumor antigen response assay and cell proliferation assay.
  • Cell viability changes The diluted cell suspension was tested for viability by trypan blue staining and the results are shown in Figure 1. The results showed that the cells maintained a high survival rate after resuscitation.
  • Proliferative capacity of cells after cryopreservation The cryopreserved cells were placed in complete medium and cultured, and the density of the cells was recorded daily. The medium was supplemented every 2-3 days and a growth curve was drawn (as shown in Figure 2). It can be seen from the figure that after the cryopreservation process, the cells still have better proliferative capacity.
  • the tumor antigen response ability of CAR-T cells before and after cryopreservation cryopreserved cells and tumor cells carrying tumor antigen were co-cultured for 1:1 overnight, and the culture supernatant was collected to detect the amount of IFNr released by CAR-T cells; The ratio of CD137 positive cells expressing CD137 was used to assess tumor antigen response ability.
  • the data before cryopreservation and the data which were further cultured for 7 days after cryopreservation were compared as shown in Fig. 3. The results showed that the cell's tumor antigen response capacity did not decrease significantly after undergoing the cryopreservation-resuscitation process.
  • the frozen cell preparation survival rate after cryopreservation for 3 months is over 90%.
  • the reconstituted frozen CAR-T cell preparation still has value-adding capabilities.
  • the resuscitated frozen CAR-T cell preparation has a reversible decrease in tumor antigen response ability and is restored after continued culture.
  • the frozen cell preparation maintains the original potency of fresh cells and can be used clinically.
  • the cells were rapidly thawed in 37 ° C waters and transferred to pre-warmed DMEM at 37 ° C, and about 0.3 ml was taken for viability detection.
  • the results showed that after the cell cryopreservation and resuscitation using the method of the present application, the recovery rate was higher than that of the cryopreservation recovery method using the cryopreservation method of the control group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种便于临床使用的冻存细胞制剂的制备与使用。具体地，本发明提供了一种冻存(冰冻)细胞制剂，所述制剂包括：(1)细胞；(2)冻存稀释液，所述的冻存稀释液包括：氯化钠水溶液、保护性蛋白，和二甲基亚砜。本发明还涉及相应的细胞复苏方式。本发明采用免洗的冻存液进行细胞冰冻制剂的制备，采用简单配药式的操作进行细胞复苏和稀释既可以进行临床使用。

Description

一种冻存细胞制剂及细胞复苏方式 技术领域
本发明属于细胞治疗领域，具体地，本发明提供了一种免洗的可静脉滴注的冰冻细胞制剂，以及使该冰冻细胞制剂使用简单化。
背景技术
细胞治疗应用时，通常采用新鲜的细胞进行静脉或局部输注，或者采用冻存的细胞经过洗涤后进行使用。新鲜的细胞在临床使用之前，一般只有不到8小时的有效期，不利于远程的运输，也不能适应临床病人病情的变化。因此，若需要在治疗领域应用到细胞，势必涉及到对细胞进行冻存和复苏的过程。
在实验室冻存复苏过程中，对冻存的细胞进行复苏洗涤的操作通常需要在洁净的环境中(如无菌室中)进行，且需要专业的生物技术人员进行操作。然而，在实际治疗的过程中，冻存复苏的过程是在普通医院中进行的，无法提供无菌室的环境，也缺乏具有相应实验技巧的人员，这限制了细胞治疗的推广使用。
综上所述，本领域迫切需要一种操作简单的细胞冻存复苏方法及相应的试剂。
发明内容
本发明采用免洗的冻存液进行细胞冰冻制剂的制备，采用简单配药式的操作进行细胞复苏和稀释既可以进行临床使用。有效的解决了细胞治疗领域的上述问题。
本发明的第一方面，提供了一种冻存(冰冻)细胞制剂，所述制剂包括：
(1)细胞；
(2)冻存液，所述的冻存液包括：氯化钠水溶液、保护性蛋白，和二甲基亚砜。
在另一优选例中，所述的细胞为选自下组的细胞：原代T细胞、扩增培养后的T细胞、基因转导后的T细胞、干细胞，或其组合。
在另一优选例中，所述的细胞为选自下组的细胞：悬浮培养的细胞和贴壁培养的细胞。
在另一优选例中，所述的贴壁培养的细胞在制备所述的冻存制剂之前预先进行消化悬浮。
在另一优选例中，所述的制剂中，细胞密度范围是1×10 5-5×10 8/ml。
在另一优选例中，所述的制剂中，氯化钠浓度为0.85％-0.95％(w/v)。
在另一优选例中，所述的制剂中，保护性蛋白浓度为10％-90％(w/v)。
在另一优选例中，所述的制剂中，保护性蛋白浓度为10-30％(w/v)。
在另一优选例中，所述的制剂中，保护性蛋白浓度为15-25％(w/v)。
在另一优选例中，所述的制剂中，二甲基亚矾浓度为5％-40％(v/v)。
在另一优选例中，所述的制剂中，二甲基亚矾浓度为5％-20％(v/v)。
在另一优选例中，所述的制剂中，二甲基亚矾浓度为8％-12％(v/v)。
在另一优选例中，所述方法包括步骤：
(a)提供待冻存的细胞和冻存稀释液，用所述的冻存稀释液重悬所述细胞，得到第一冻存混合物；其中，所述的冻存稀释液包括以下组分：氯化钠水溶液，和保护性蛋白；
(b)在所述的第一冻存混合物中加入冻存稀释液，混匀，得到第二冻存混合物；
(c)转移所述的第二冻存混合物至容器中，进行程序降温至-80℃以下，得到所述的冻存细胞制剂。
在另一优选例中，步骤(b)中所述的冻存液的体积Vb和步骤(a)中所述的冻存稀释液的体积Va之比Vb：Va＝1:0.8-1.2。
在另一优选例中，所述的容器为冻存袋或冻存管。
在另一优选例中，所述的冻存稀释液包括：氯化钠水溶液，和保护性蛋白。
在另一优选例中，所述的冻存稀释液中，氯化钠浓度为0.85％-0.95％(w/v)。
在另一优选例中，所述的冻存稀释液中，保护性蛋白浓度为10％-90％(w/v)。
在另一优选例中，所述的制剂中，保护性蛋白浓度为10-30％(w/v)。
在另一优选例中，所述的制剂中，保护性蛋白浓度为15-25％(w/v)。
本发明的第二方面，提供了一种冻存细胞复苏方法，包括步骤：
(i)提供如本发明第一方面中所述的冻存细胞制剂；
(ii)将所述的冻存细胞制剂置于35-40℃的恒温设备中进行复苏，得到复苏后 的细胞-冻存液复合物；
(iii)用注射器或一次性使用连接器将所述制剂中的细胞转移至注射载体中。
在另一优选例中，所述的复苏还包括步骤：对细胞进行活率检测，若活率符合使用要求，则用于临床使用。
在另一优选例中，所述的恒温设备为恒温水浴锅。
在另一优选例中，所述的细胞解冻时间为30秒到3分钟。
在另一优选例中，所述的注射载体为可静脉注射的溶液，优选地选自下组：氯化钠注射液、复方电解质注射液、氨基酸注射液。
应理解，在本发明范围内中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合，从而构成新的或优选的技术方案。限于篇幅，在此不再一一累述。
附图说明
图1为实施例1中冻存前和复苏后细胞活率的变化对比图；
图2为实施例1中冻存复苏后的细胞增殖能力曲线图；
图3为实施例1中冻存前和冻存后CAR-T细胞的肿瘤抗原应答能力对比图；
图4为不同冻存方式(程序)的比较。
具体实施方式
本发明人经过长期而深入的研究，设计了一种操作简便的细胞冻存-复苏方法，及所使用的相应冻存液。所述的方法可以在普通实验室环境下，由医疗人员方便地进行，因此可以用作细胞治疗过程中的冻存-复苏方法。基于上述发现，发明人完成了本发明。
冻存细胞制剂
如本文所用，术语“冻存细胞制剂”和“冰冻细胞制剂”可互换使用，均指在低温(如-80℃下，或液氮环境中)状态下保存的含有治疗活性细胞的制剂。
本发明的冻存(冰冻)细胞制剂包括以下组分：
(1)细胞；
(2)冻存液，所述的冻存液包括：氯化钠水溶液、保护性蛋白，和二甲基亚砜。
所述的细胞是可以用于细胞治疗的活性细胞，其种类没有特别的限制，本发明的优选实施例中，所述的细胞为选自下组的细胞：原代T细胞、扩增培养后的T细胞、基因转导后的T细胞、干细胞，或其组合。
本发明的细胞类型没有特别的限制，在另一优选例中，所述的细胞为选自下组的细胞：悬浮培养的细胞和贴壁培养的细胞。较佳地，所述的贴壁培养的细胞在制备所述的冻存制剂之前，预先进行消化悬浮。
所述的制剂中，所述的细胞密度范围没有特别的限制，例如可以是1×10 5-5×10 8/ml。
优选地，所述的制剂中，氯化钠浓度为0.85％-0.95％(w/v)。
在另一优选实施例中，所述的制剂中，保护性蛋白浓度为10％-90％(w/v)。
在另一优选实施例中，所述的制剂中，二甲基亚矾浓度为5％-40％(v/v)。
细胞冻存复苏方法
本发明还提供了一种细胞冻存-复苏的方法，所述的方法包括步骤：
(a)提供待冻存的细胞和冻存稀释液，用所述的冻存稀释液重悬所述细胞，得到第一冻存混合物；其中，所述的冻存稀释液包括以下组分：氯化钠水溶液，和保护性蛋白；
(b)在所述的第一冻存混合物中加入所述的冻存液，混匀，得到第二冻存混合物；
(c)转移所述的第二冻存混合物至容器中，进行程序降温至-80℃以下，得到冻存细胞制剂。
其中，步骤(b)中所述的冻存液的体积Vb和步骤(a)中所述的冻存稀释液的体积Va之比Vb：Va＝1:0.8-1.2。当然，根据待冻存的细胞种类，冻存温度等条件的不同，上述二者的比例可以略有差异。
所述的容器没有特别的限制，优选为可以用注射器刺穿容器表面进行吸液的容器。在本发明的优选实施例中，所述的容器为冻存袋或冻存管。采用上述装置，可以最大程度地避免普通实验室环境所带来的污染。
所述的冻存的细胞可以在常规非无菌环境下进行复苏，在本发明的优选实施例中，所述的复苏过程包括步骤：
(i)提供所述的冻存细胞制剂；
(ii)将所述的冻存细胞制剂置于35-40℃的恒温设备中进行复苏，得到复苏后的细胞-冻存液复合物；
(iii)用注射器或一次性使用连接器将所述制剂中的细胞转移至注射载体中。
在另一优选例中，所述的复苏还包括步骤：对细胞进行活率检测，若活率符合使用要求，则用于临床使用。
所述的恒温设备没有特别的限制，可以为实验室中常用的恒温设备(如恒温水浴锅)。
在另一优选例中，所述的细胞解冻时间为30秒到3分钟。
所述的注射载体没有特别的限制，优选可以是可静脉注射的溶液，更优选地选自下组：氯化钠注射液、复方电解质注射液、氨基酸注射液。
本发明的优选实施例中，在进行冻存前，先采用生理盐水对收集的细胞进行洗涤，确保各项残留符合产品临床使用要求。冻存稀释液除不含二甲基亚砜外，其他成分与冻存液的成分相同。根据冻存规格，用冻存稀释液重悬细胞，使细胞浓度为终浓度的2倍，再缓缓添加等体积的冻存液，充分混匀。将细胞悬液转移至冻存袋(或冻存管)中，采用1-2℃/min的降温速度进行程序降温。降温至零下80℃以下时，转移至液氮冰箱中存储。
使用时从液氮冰箱中取出冰冻制剂，在37℃条件下快速解冻。解冻后用注射剂或一次性使用连接器转移至生理盐水中。对稀释的细胞制剂进行活率检测。活率符合使用要求后进行临床使用。
与现有技术相比，本发明的主要优点包括：
(1)利用本发明制备的细胞制剂可以长期存储后依然保持高的细胞活率，便于从制备单位到使用医院的远程运输。
(2)本发明涉及的细胞冻存制剂全部采用了辅料级或药品级的试剂，可以安全的在临床进行应用。
(3)利用本发明的使用方式对冻存细胞制剂进行复苏操作，可以免去细胞制 剂操作对无菌环境的严苛要求，可以让一名未经过培训的护士轻松掌握冻存细胞的复苏并保持高的细胞活率。
(4)利用本发明的使用方式对冻存细胞制剂进行复苏操作，可以保持细胞的生物学活性。
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。除非另外说明，否则百分比和份数按重量计算。
实施例1
冰冻细胞制剂的冻存容器为冻存袋。细胞类型为CAR-T细胞。冻存规格2×10 7/10ml。冰冻细胞制剂的组分如下表所示。将所述的CAR-T细胞与100ml冻存3个月后，在37℃水浴中解冻2分钟，用注射器将解冻的细胞稀释至100ml生理盐水中。取稀释的细胞进行活率检测、肿瘤抗原应答检测和细胞增殖能力检测。
序号 组分 含量
1 细胞 2×10 7/ml
2 氯化钠 0.9％(w/v)
3 人血清白蛋白 20％(w/v)
4 二甲基亚砜 10％(v/v)
细胞活率变化：稀释的细胞悬液用台盼蓝染色的方法进行活率检测，结果如图1中所示。结果显示，复苏后细胞保持了较高的存活率。
冻存后细胞的增殖能力：将冻存复苏的细胞置于完全培养基中继续培养，每天记录细胞的密度。每隔2-3天补充培养基，绘制生长曲线(如图2中所示)。从图中可见，在冻存复苏过程后，细胞仍然具有较好的增殖能力。
冻存前后CAR-T细胞的肿瘤抗原应答能力：冻存复苏的细胞和携带肿瘤抗原的肿瘤细胞1:1共培养过夜，收集培养上清液检测CAR-T细胞释放的IFNr量；收集细胞检测CD3阳性细胞表达CD137的比例来评估肿瘤抗原应答能力。冻存前的数据和冻存后继续培养7天的数据作为对比，对比图如图3中所示。结果显示，在经历了冻存-复苏过程后，细胞的肿瘤抗原应答能力没有明显下降。
结论：冻存3个月复苏的冰冻细胞制剂活率达到90％以上。复苏的冰冻CAR-T细胞制剂依然具有增值能力。复苏的冰冻CAR-T细胞制剂，发生肿瘤抗原应答能力的可逆下降，继续培养后得到恢复。总之该冰冻细胞制剂保持了新鲜细胞原有的效能，可以再临床应用。
实施例2不同冻存程序下细胞复苏率对比
细胞在不同冻存程序冻存后，迅速在37℃水域中解冻并转移至37℃预热的DMEM中，取约0.3ml进行活率检测。结果显示，采用本申请方法进行细胞冻存复苏后，复苏率高于采用对照组冻存复苏方法进行冻存复苏后的复苏率。
在本发明提及的所有文献都在本申请中引用作为参考，就如同每一篇文献被单独引用作为参考那样。此外应理解，在阅读了本发明的上述讲授内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。

Claims (10)

  1. 一种冻存(冰冻)细胞制剂，其特征在于，所述制剂包括：
    (1)细胞；
    (2)冻存液，所述的冻存液包括：氯化钠水溶液、保护性蛋白，和二甲基亚砜。
  2. 如权利要求1所述的制剂，其特征在于，所述的细胞为选自下组的细胞：原代T细胞、扩增培养后的T细胞、基因转导后的T细胞、干细胞，或其组合。
  3. 如权利要求1所述的制剂，其特征在于，所述的细胞为选自下组的细胞：悬浮培养的细胞和贴壁培养的细胞。
  4. 如权利要求1所述的制剂，其特征在于，所述的制剂中，细胞密度范围是1×10 5-5×10 8/ml。
  5. 如权利要求1所述的制剂，其特征在于，所述的制剂中，氯化钠浓度为0.85％-0.95％(w/v)。
  6. 如权利要求1所述的制剂，其特征在于，所述的制剂中，保护性蛋白浓度为10％-90％(w/v)。
  7. 如权利要求1所述的制剂，其特征在于，所述的制剂中，二甲基亚矾浓度为5％-40％(v/v)。
  8. 如权利要求1所述的制剂的制备方法，其特征在于，所述方法包括步骤：
    (a)提供待冻存的细胞和冻存稀释液，用所述的冻存稀释液重悬所述细胞，得到第一冻存混合物；其中，所述的冻存稀释液包括以下组分：氯化钠水溶液，和保护性蛋白；
    (b)在所述的第一冻存混合物中加入冻存稀释液，混匀，得到第二冻存混合物；
    (c)转移所述的第二冻存混合物至容器中，进行程序降温至-80℃以下，得到所述的冻存细胞制剂。
  9. 一种冻存细胞复苏方法，其特征在于，包括步骤：
    (i)提供如权利要求1中所述的冻存细胞制剂；
    (ii)将所述的冻存细胞制剂置于35-40℃的恒温设备中进行复苏，得到复苏后的细胞-冻存液复合物；
    (iii)用注射器或一次性使用连接器将所述制剂中的细胞转移至注射载体中。
  10. 如权利要求9所述的方法，其特征在于，所述的注射载体为可静脉注射的溶液，优选地选自下组：氯化钠注射液、复方电解质注射液、氨基酸注射液。
PCT/CN2018/088246 2017-05-24 2018-05-24 一种冻存细胞制剂及细胞复苏方式 WO2018214943A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NZ759568A NZ759568A (en) 2017-05-24 2018-05-24 Cell cryopreservation formulation and cell recovery method
JP2020515812A JP7303184B2 (ja) 2017-05-24 2018-05-24 凍結保存細胞製剤および細胞再生方法
KR1020197038096A KR102350423B1 (ko) 2017-05-24 2018-05-24 세포 동결 보존 제제 및 세포 소생 방법
EP18805534.7A EP3632207A4 (en) 2017-05-24 2018-05-24 FORMULATION FOR CELL PRESERVATION AND CELL RECOVERY METHOD
AU2018272688A AU2018272688B2 (en) 2017-05-24 2018-05-24 Cell cryopreservation formulation and cell recovery method
US16/616,216 US20200170242A1 (en) 2017-05-24 2018-05-24 Cell cryopreservation formulation and cell recovery method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710375424.XA CN108925548A (zh) 2017-05-24 2017-05-24 一种冻存细胞制剂及细胞复苏方式
CN201710375424.X 2017-05-24

Publications (1)

Publication Number Publication Date
WO2018214943A1 true WO2018214943A1 (zh) 2018-11-29

Family

ID=64396262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/088246 WO2018214943A1 (zh) 2017-05-24 2018-05-24 一种冻存细胞制剂及细胞复苏方式

Country Status (8)

Country Link
US (1) US20200170242A1 (zh)
EP (1) EP3632207A4 (zh)
JP (1) JP7303184B2 (zh)
KR (1) KR102350423B1 (zh)
CN (1) CN108925548A (zh)
AU (1) AU2018272688B2 (zh)
NZ (1) NZ759568A (zh)
WO (1) WO2018214943A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
CN113994951A (zh) * 2021-11-17 2022-02-01 晋文娟 一种cik细胞冻存液及冻存方法
CN114097771B (zh) * 2021-12-15 2022-10-14 珠海贝索细胞科学技术有限公司 一种细胞保存液及其应用和细胞保存方法
CN115136955A (zh) * 2022-08-03 2022-10-04 深圳宾德生物技术有限公司 细胞冻存液及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067480A1 (en) * 2002-10-04 2004-04-08 Organ Recovery Systems, Inc. Method for treatment of cellular materials with sugars prior to preservation
CN102907416A (zh) * 2012-08-01 2013-02-06 臻景生物技术（上海）有限公司 一种可维持细胞活性的组织冻存液
CN103461322A (zh) * 2012-06-07 2013-12-25 臻景生物技术（上海）有限公司 用于冻存复苏后的细胞的保存液
CN103583511A (zh) * 2012-09-03 2014-02-19 四川新生命干细胞科技股份有限公司 一种间充质干细胞冻存液及注射液
CN104430301A (zh) * 2014-11-18 2015-03-25 成都康华生物制品有限公司 一种提高人二倍体细胞存活率的方法
CN105325402A (zh) * 2015-11-13 2016-02-17 黄林海 一种用于玻璃化冻存骨髓间充质干细胞的冻存保护剂
CN105477017A (zh) * 2015-12-03 2016-04-13 深圳爱生再生医学科技有限公司 治疗糖尿病足的混合干细胞制剂及其制备方法
CN105660606A (zh) * 2016-03-10 2016-06-15 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20070025961A1 (en) * 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
CN102119936B (zh) * 2011-03-07 2012-12-12 李荣旗 制备利用人羊膜间充质细胞治疗缺血性脑损伤注射液的方法及其注射液
CN102908364A (zh) * 2012-11-14 2013-02-06 青岛奥克生物开发有限公司 一种间充质干细胞注射液及其制备方法和在制备治疗儿童扩张型心肌病药物中的应用
SG11201603407VA (en) * 2013-11-04 2016-05-30 Isopogen Pty Ltd Cell culture method
WO2016007506A1 (en) * 2014-07-07 2016-01-14 Targazyme, Inc. Manufacture and cryopreservation of fucosylated cells for therapeutic use
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
CN104857022A (zh) * 2015-05-21 2015-08-26 北京青藤谷禧干细胞科技研究院有限公司 一种间充质干细胞注射液、制备方法及其应用
CN105394026B (zh) * 2015-10-31 2017-09-29 北京军科联合干细胞生物科技有限公司 一种造血干细胞冻存新方法
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
CN106665560B (zh) * 2017-01-16 2021-02-05 哈尔滨医科大学 一种直接静脉回输的免疫细胞冻存液及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067480A1 (en) * 2002-10-04 2004-04-08 Organ Recovery Systems, Inc. Method for treatment of cellular materials with sugars prior to preservation
CN103461322A (zh) * 2012-06-07 2013-12-25 臻景生物技术（上海）有限公司 用于冻存复苏后的细胞的保存液
CN102907416A (zh) * 2012-08-01 2013-02-06 臻景生物技术（上海）有限公司 一种可维持细胞活性的组织冻存液
CN103583511A (zh) * 2012-09-03 2014-02-19 四川新生命干细胞科技股份有限公司 一种间充质干细胞冻存液及注射液
CN104430301A (zh) * 2014-11-18 2015-03-25 成都康华生物制品有限公司 一种提高人二倍体细胞存活率的方法
CN105325402A (zh) * 2015-11-13 2016-02-17 黄林海 一种用于玻璃化冻存骨髓间充质干细胞的冻存保护剂
CN105477017A (zh) * 2015-12-03 2016-04-13 深圳爱生再生医学科技有限公司 治疗糖尿病足的混合干细胞制剂及其制备方法
CN105660606A (zh) * 2016-03-10 2016-06-15 广州赛莱拉干细胞科技股份有限公司 一种细胞冻存液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3632207A4 *

Also Published As

Publication number Publication date
NZ759568A (en) 2023-01-27
CN108925548A (zh) 2018-12-04
KR102350423B1 (ko) 2022-01-11
EP3632207A1 (en) 2020-04-08
KR20200073171A (ko) 2020-06-23
JP7303184B2 (ja) 2023-07-04
EP3632207A4 (en) 2021-03-10
AU2018272688A1 (en) 2019-12-19
US20200170242A1 (en) 2020-06-04
AU2018272688B2 (en) 2021-05-27
JP2020520680A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
WO2018214943A1 (zh) 一种冻存细胞制剂及细胞复苏方式
CN107148967B (zh) 一种抗原特异性t淋巴细胞冻存液及其制备方法和应用
CN108207930B (zh) 一种鸡尾酒式冷冻保护剂及其应用
AU2014221330B2 (en) Combined organ and hematopoietic cells for transplantation tolerance of grafts
CN105076116B (zh) 一种细胞冻存液及其应用与巨核祖细胞的冻存方法
JP6850360B2 (ja) 臨床使用可能な細胞凍結保存液
JP6531256B2 (ja) 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
CN103732247A (zh) 用于加工含有活细胞的生物药物的方法
CN101166541A (zh) 用于修复心脏组织的方法和组合物
CN107912425B (zh) 一种可输液的细胞冻存管试剂盒及其应用
JP5379340B2 (ja) ヒト自己前駆幹細胞を培養する培地とその応用
CN101914497B (zh) 临床用n-cik细胞培养、质量控制鉴定试剂盒及应用
WO2021240169A1 (en) Cryopreserving macrophages
CN101188941A (zh) 用于治疗糖尿病的方法和组合物
WO2021190620A1 (zh) 细胞保存液及其试剂盒
WO2018214942A1 (zh) 一种冻存细胞试剂盒
CN114391536B (zh) 一种间充质干细胞冻存液
CN114736856A (zh) 一种犬胎盘间充质干细胞的制备方法及其应用
CN115802889A (zh) 生物样品低温储存
US8642027B2 (en) Compositions and methods for modulating ischemic injury
CN113133444B (zh) 脐带组织冻存液及其制备方法、脐带组织的冻存方法及培养方法
CN110882276A (zh) 细胞治疗组合物及治疗血管病变的方法
JP2022502080A (ja) Ｗｎｔ−活性化脂肪由来幹細胞装置、方法およびシステム
CN113416701B (zh) 一种nk细胞培养基及培养方法
Veronesi et al. cGMP-compliant transportation conditions for a prompt therapeutic use of marrow mesenchymal stromal/stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18805534

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020515812

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018272688

Country of ref document: AU

Date of ref document: 20180524

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018805534

Country of ref document: EP

Effective date: 20200102